文献速递颅颌面外科显微修复重建

面部移植18年:不良结局与挑战

18 years of face transplantation: Adverse outcomes and challenges.
PubMed 文献 · J Plast Reconstr Aesthet Surg · 2023-09-15

该系统综述检索PubMed、MEDLINE、Cochrane、Google及Google Scholar数据库至2023年4月,纳入28篇报告。在46例患者共48次手术中,14例(29%)出现不良结局,包括7例移植物丢失(14.6%)和10例患者死亡(21.7%)。慢性排斥是移植物丢失的首要原因,移植至不可逆排斥的中位时间为90个月(IQR 88.5-102);死亡主要原因为感染性并发症,其次为恶性肿瘤、免疫抑制依从性差和自杀,死亡中位时间为48.5个月(IQR 19-122)。

要点

  • 46例患者48次面部移植手术中,14例(29%)出现不良结局。
  • 移植物丢失7例(14.6%),慢性排斥是首要原因,中位时间90个月。
  • 患者死亡10例(21.7%),主要死因为感染性并发症。

核心结论

  • 据作者所知,这是首个全面综述面部移植不良结局的研究;考虑到主要并发症发生率高、病例异质性及单中心模式、缺乏已发表的标准诊疗规范,面部移植团队制定共识对该领域发展至关重要。

研究设计与样本

  • 按PRISMA指南对PubMed、MEDLINE、Cochrane、Google和Google Scholar数据库进行系统综述,检索截至2023年4月。
  • 纳入提供面部同种异体移植物丢失、移除及患者死亡病例详情的文章,并评估在线文章和媒体报道以纳入同行评议文献未披露的信息。
  • 联系面部移植中心以获取单例面部移植病例的最新随访信息;检索得到1006篇报告,最终纳入28篇。

主要发现

  • 46例患者共实施48次手术,14例(29%)出现不良结局。
  • 移植物丢失7例(14.6%),慢性排斥是首要原因,移植至不可逆排斥的中位时间为90个月(IQR 88.5-102)。
  • 患者死亡10例(21.7%),主要死因为感染性并发症,其次为恶性肿瘤、免疫抑制依从性差和自杀。
  • 死亡中位时间为48.5个月(IQR 19-122)。

临床怎么用

  • 作者认为,考虑到主要并发症发生率高、病例异质性及单中心模式、缺乏已发表的标准诊疗规范,面部移植团队制定共识对该领域发展至关重要。

局限性

  • 原文未报告局限性。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

BACKGROUND: Since the first procedure performed in 2005, face transplantation has been debated as viable approach for the treatment of severe craniofacial defects. Despite the benefits provided, the experience in face allotransplantation has brought to light a significant risk of complications, including allograft removal or loss, and mortality. The present study is intended to provide an updated review on complications and major challenges witnessed over 18 years of experience in the field. METHODS: A systematic review of PubMed, MEDLINE, Cochrane, Google, and Google Scholar databases on face transplantation was conducted according to PRISMA guidelines up to April 2023. Articles providing details on cases of face allograft loss, removal, and patient death were included. Online articles and media reports were assessed to include information not disclosed in peer-reviewed literature. Face transplant centers were contacted to have updated follow-up information on single-face transplant cases. RESULTS: The search yielded 1006 reports, of which 28 were included. On a total of 48 procedures performed in 46 patients, adverse outcomes were gleaned in 14 cases (29%), including seven allograft losses (14.6%), and the death of ten patients (21.7%). Chronic rejection was the leading cause of allograft loss, with a median time from transplant to irreversible rejection of 90 months (IQR 88.5-102). The main causes of death were infectious complications, followed by malignancies, non-compliance to immunosuppression, and suicide. The median time to death was 48.5 months (IQR 19-122). CONCLUSIONS: To the best of our knowledge, this is the first study providing a comprehensive review of adverse outcomes in face transplantation. Considering the high rate of major complications, the heterogeneity of cases and single-center approaches, and the absence of published standards of care, the development of a consensus by face transplant teams holds the key to the field's advancement.

来源:J Plast Reconstr Aesthet Surg,查看原文。版权归原作者所有。

引用

  1. Longo B, Pomahac B, Giacalone M, et al. 18 years of face transplantation: Adverse outcomes and challenges. J Plast Reconstr Aesthet Surg. 2023. PMID: 37879143. doi:10.1016/j.bjps.2023.09.043

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。